Data as of Jul 25, 2026 · Based on 2,718,867 AI responses across 9,511 prompts · See how Parse measures this
Breezula (clascoterone) is a topical androgen receptor antagonist being developed for androgenetic alopecia (AGA). Phase 3 results showed statistically significant improvements in Target-Area Hair Count, with safety follow-up and plans for regulatory submissions in the US and Europe. Cosmo Pharmaceuticals positions Breezula as potentially the first topical AR inhibitor approved for AGA, pending regulatory authorization.
Parse Score